Rotavirus [serotypes G1, G2, G3, G4, P1] (pentavalent) vaccine is a Live Attenuated Vaccine owned by Merck & Co, and is involved in 25 clinical trials, which were completed.

RotaTeq live oral vaccine replicates in the small intestine and induces immunity. There are various types of rotaviruses that cause gastroenteritis. They vary in that they may carry different antigens. An antigen is a specific structure that the body can recognise as ‘foreign’ and against which it can make an antibody, a special protein that can neutralise or destroy the antigen. RotaTeq contains viruses that carry the antigens for some of the most commonly occurring types of rotaviruses. When a child is given the vaccine, the immune system (the system that fights diseases) makes antibodies against these antigens, which help prevent infections caused by rotaviruses that occur naturally that carry the same or very similar antigens.

The revenue for Rotavirus [serotypes G1, G2, G3, G4, P1] (pentavalent) vaccine is expected to reach a total of $18.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Rotavirus [serotypes G1, G2, G3, G4, P1] (pentavalent) vaccine NPV Report.

Rotavirus [serotypes G1, G2, G3, G4, P1] (pentavalent) vaccine is currently owned by Merck & Co.

Rotavirus [serotypes G1, G2, G3, G4, P1] (pentavalent) vaccine Overview

Rotavirus pentavalent live oral vaccine (RotaTeq) in which reassortants isolated from human and bovine hosts and produced in Vero cells. It contains five live rotavirus strains (G1, G2, G3, G4 and P1[8]). It is formulated as solution for oral route of administration. RotaTeq is indicated for the active immunisation of infants from the age of 6 weeks to 32 weeks for prevention of gastroenteritis due to rotavirus infection. RotaTeq is a live viral vaccine that replicates in the small intestine and induces immunity.

Merck & Co Overview

Merck & Co (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

The company reported revenues of (US Dollars) US$48,704 million for the fiscal year ended December 2021 (FY2021), an increase of 17.3% over FY2020. In FY2021, the company’s operating margin was 25.7%, compared to an operating margin of 12% in FY2020. In FY2021, the company recorded a net margin of 26.8%, compared to a net margin of 17% in FY2020. The company reported revenues of US$14,959 million for the third quarter ended September 2022, an increase of 2.5% over the previous quarter.

Quick View – Rotavirus [serotypes G1, G2, G3, G4, P1] (pentavalent) vaccine

Report Segments
  • Innovator (NME)
Drug Name
  • Rotavirus [serotypes G1, G2, G3, G4, P1] (pentavalent) vaccine
Administration Pathway
  • Oral
Therapeutic Areas
  • Infectious Disease
Key Companies
  • Sponsor Company: Merck & Co
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.